Drug Trial Radar · NCT00338286
A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
Last checked: Nov 19, 2026Latest source record: Mar 19, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,098
Actual
Start
Mar 2, 2006
Primary completion
Jul 7, 2014
Study completion Jan 31, 2017
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Jun 20, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the impact on tumor progression as evaluated by progression-free survival (PFS) of epoetin alfa plus standard supportive care as compared with standard supportive care alone (packed red blood cell (RBC) transfusions), for treating anemia according to label guidance in patients with metastatic breast cancer receiving standard chemotherapy.
Conditions
- Breast Cancer
- Neoplasm Metastasis
Interventions
Standard supportive care (packed RBC transfusion)Other
Per doctor prescription
epoetin alfa + packed RBC transfusionDrug
40,000 IU SC once a week.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free SurvivalTime frame: From the date of randomization to the date of disease progression (PD) or death, whichever occurred first (up to 8.4 years)
Locations
174 sites in 21 countries. Site status is shown where the registry gives one.
Site not named
Anaheim, California
Site not named
Gainesville, Florida
Site not named
Miami, Florida
Site not named
New Port Richey, Florida
Site not named
Rockledge, Florida
Site not named
Hazard, Kentucky
Site not named
Alexandria, Louisiana
Site not named
Marrero, Louisiana
Site not named
Jackson, Mississippi
Site not named
Lake Success, New York
Site not named
Staten Island, New York
Site not named
Philadelphia, Pennsylvania
Site not named
Corpus Christi, Texas
Site not named
Houston, Texas
Site not named
Buenos Aires, Argentina
Site not named
Capital Federal, Argentina
Site not named
Ciudad Autonoma de Buenos Airess, Argentina
Site not named
Córdoba, Argentina
Site not named
La Plata, Argentina
Site not named
Mendoza, Argentina
Site not named
Quilmes, Argentina
Site not named
Rosario, Argentina
Site not named
Santa Fe, Argentina
Site not named
Barretos, Brazil
Site not named
Curitiba, Brazil
Site not named
Goiânia/Go, Brazil
Site not named
Ijuí, Brazil
Site not named
Jaú, Brazil
Site not named
Piracicaba, Brazil
Site not named
Porto Alegre, Brazil
Site not named
Ribeirão Preto/Sp, Brazil
Site not named
Santo André, Brazil
Site not named
São José do Rio Preto, Brazil
Site not named
São Paulo, Brazil
Site not named
São Paulol, Brazil
Site not named
Plovdiv, Bulgaria
Site not named
Rousse, Bulgaria
Site not named
Sofia, Bulgaria
Site not named
Stara Zagora, Bulgaria
Site not named
Varna, Bulgaria
Showing 40 of 174 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.